governance

Jeffrey Nugent , , , Chairman and CEO

View bioHide bio

Jeffrey Nugent joined Sientra in 2014 as a board member, prior to becoming the Chairman and CEO in 2015. Mr. Nugent’s experience includes serving as the CEO and Worldwide President of Neutrogena, where he led the acquisition by Johnson & Johnson. Neutrogena is regarded as one of the most successful acquisitions in J&J history. Following Neutrogena, Mr. Nugent became the President and CEO of Revlon, where he led a turnaround in profitability and a global initiative of new product innovation. He was Founder, President and CEO of Precision Dermatology, a multi-channel dermatology and skin care company he established in 2010. The company grew both organically and by M&A and was acquired by Valeant Pharmaceuticals in 2013. He began his career at Johnson & Johnson where he held a number of senior responsibilities in general management, research, finance, marketing and manufacturing across pharmaceutical, medical device and consumer franchises. He was appointed Vice President of Worldwide Quality. Most recently, Mr. Nugent had been Interim President, Chief Executive Officer and a Director of Biolase, Inc. Mr. Nugent has also served as Chairman, Director, President and Chief Executive Officer of a number of aesthetic medicine, medical device and consumer focused companies including Bioform, Inc. prior to its acquisition by Merz Aesthetics, Inc. He has also served on the Board of the Child Welfare League of America. Mr. Nugent holds a B.S. in mathematics from St. Joseph's College and earned an M.B.A. in finance and marketing from Loyola University in Chicago. He served as an Artillery Officer in the U.S. Army while assigned to military intelligence at the Pentagon.

Nicholas Simon , , , Director

View bioHide bio

Nicholas Simon has served as Chairman of the board since March 2012. Mr. Simon has been a Managing Director of Clarus Ventures, LLC, a venture capital firm focused on life sciences companies, since the firm's inception in 2005. Mr. Simon has been a General Partner of MPM BioVentures III, a healthcare venture capital fund, since 2001. From 2000 to 2001, Mr. Simon was Chief Executive Officer and Founder of Collabra Pharma, Inc., a pharmaceutical company. Prior to that, Mr. Simon served in various management positions at Genentech, Inc., including as Vice President of Business and Corporate Development. Mr. Simon has served on the board of directors of Achillion Pharmaceuticals, Inc. and Avanir Pharmaceuticals, Inc. and numerous private companies. He is also on the foundation board of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a B.S. in microbiology from the University of Maryland and earned his M.B.A. in marketing from Loyola University. We believe Mr. Simon's experience as a director advising several companies, as well as his significant financial and investment experience qualifies him to serve as one of our directors.

Timothy Haines , , , Director

View bioHide bio

Timothy Haines has served as a director of the Company since October 2013. Mr. Haines has been a partner at Abingworth, a life science and healthcare private investment firm, since 2005. Prior to that, Mr. Haines was chief executive of Astex Therapeutics Limited. Mr. Haines was with Astex Therapeutics Limited for more than five years and was a director of the company at it sale to Otsuka in October 2013. Previously, he was chief executive of two divisions of the publicly listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of senior management positions in the United States and Europe. Mr. Haines currently serves as a director of Lombard Medical Technologies Inc. and Pixium Vision. He has served as a director of Astex Pharmaceuticals and Xcounter AB and numerous private companies. He is a former director of the Biotechnology Industry Association and currently sits on the Venture Committee of the British Venture Capital Association. Mr. Haines has a B.Sc. from Exeter University and an M.B.A. from INSEAD. We believe Mr. Haines' valuable experience gained from the executive positions he held at biotechnology and healthcare companies, as well as his experience as a director advising several companies, qualifies him to serve as one of our directors.

Kevin O'Boyle , , , Director

View bioHide bio

Kevin O'Boyle has served as a director of the Company since July 2014. From December 2010 to July 2011, Mr. O'Boyle served as Senior Vice President and Chief Financial Officer at Advanced BioHealing, Inc. until it was acquired by Shire Plc. From early 2003 to September 2009, Mr. O'Boyle served as Chief Financial Officer of NuVasive, Inc. Mr. O'Boyle currently serves as a director of GenMark Diagnostics, Inc., Durata Therapeutics, Inc., Tornier N.V. and Zeltiq Aesthetics, Inc. Mr. O'Boyle received a B.S. in accounting from Rochester Institute of Technology and completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School. We believe Mr. O'Boyle is qualified to serve as one of our directors based on his financial and accounting expertise and his significant experience and familiarity with companies in the medical device and aesthetics industries.

R. Scott Greer , , , Director

View bioHide bio

R. Scott Greer has served as a director of the Company since July 2014. Mr. Greer founded Numenor Ventures, LLC, a venture capital firm focused on life sciences companies, and has served as its Managing Director since June 2002. Prior to that, in 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He also served as a director of Abgenix from 1996 and chairman of the board from 2000 until the acquisition of Abgenix by Amgen, Inc. in April 2006. Prior to Abgenix's formation, Mr. Greer held senior management positions at Cell Genesys, Inc., a biotechnology company, initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development. Mr. Greer currently serves as a director of Versartis, Inc., StemCells, Inc. and Nektar Therapeutics. He previously served as chairman of the board of Ablexis, LLS, Inogen, Inc., and Sirna Therapeutics and as a director of Illumina, Inc., CV Therapeutics, Inc. and Auspex, Inc. He has also previously served on the board of numerous private companies. Mr. Greer received his B.A. in economics from Whitman College, earned his M.B.A. in business administration from Harvard University and was a certified public accountant. We believe Mr. Greer's significant financial, business and management expertise, coupled with his extensive experience as a director of multiple life science companies, qualifies him to serve as one of our directors.

Philippe Schaison , , Dr. , , Director

View bioHide bio

Dr. Philippe Schaison has served as a director of the Company since February 2017. Since November, 2016, Dr. Schaison has also served as CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Previously, Dr. Schaison served as President of Allergan’s U.S. aesthetic and dermatology business. In that position, he led the Facial Aesthetic, Plastic and MedDerm/Skin Medical business unit, an organization of over 2,000 professionals focused on the company’s Botox® and fillers franchises. Prior to joining Allergan, Dr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York. Earlier, Dr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines and as Vice President of Global Skin Care for Johnson & Johnson, with P&L responsibility for Aveeno, Clean & Clear, Lubriderm, and Ambi, and in executive positions at L'Oréal. Dr. Schaison sits on the Board of the Galien Foundation and SENTÉ, Inc., a privately held specialty aesthetics company. He earned his MBA (Marketing) from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris.

Keith Sullivan , , , Director

View bioHide bio

Mr. Sullivan most recently was Chief Commercial Officer and President, North America of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand. Mr. Sullivan led the restructuring of the global commercial organization resulting in a nearly 50% 4-year CAGR leading to an acquisition this year by Allergan. Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center and Coherent Medical. Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary.

NASD: SIEN

Stock Quote: NASD

$14.88 +0.00
Volume 130,900
Previous Close 14.88
Intraday High 15.34
Intraday Low 14.53
Pricing delayed 20 minutes
Price Change % Change +0% 52 Week High 16.68 52 Week Low 7.20 Today's Open 14.80 Dec 14, 2017 05:00 PM

Investor Contact

Sientra Investor Relations
855.344.5714
IR@sientra.com